LYL1 activity is required for the maturation of newly formed blood vessels in adulthood

Blood

Volumn 115, Issue 25, 2010, Pages 5270-5279

  Pirot, Nelly ^a,b,e   Deleuze, Virginie ^a,b   El Hajj, Rawan ^a,b   Dohet, Christiane ^a,b   Sablitzky, Fred ^c   Couttet, Philippe ^d   Mathieu, Danièle ^a,b   Pinet, Valérie ^a,b  

^a CNRS   (France)

^b UNIV MONTPELLIER   (France)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

^e INSTITUT DE RECHERCHE EN CANCÉROLOGIE DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; HELIX LOOP HELIX PROTEIN; LYL1 PROTEIN; MATRIGEL; TRANSCRIPTION FACTOR TAL1; UNCLASSIFIED DRUG; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; CADHERIN; LEUKOCYTE ANTIGEN; LYL1 PROTEIN, HUMAN; LYL1 PROTEIN, MOUSE; ONCOPROTEIN; TAL1 PROTEIN, MOUSE; TUMOR PROTEIN; VASCULAR ENDOTHELIAL CADHERIN;

ADULT; ADULTHOOD; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER TRANSPLANTATION; CELL MATURATION; CELL MEMBRANE PERMEABILITY; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; MOLECULE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PERICYTE; PHENOTYPE; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; BIOSYNTHESIS; EXPERIMENTAL NEOPLASM; GENE EXPRESSION REGULATION; GENETICS; HEMATOPOIESIS; METABOLISM; MOUSE MUTANT; VASCULARIZATION;

ANGIOPOIETIN-2; ANIMALS; ANTIGENS, CD; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CADHERINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIESIS; HUMANS; MICE; MICE, MUTANT STRAINS; NEOPLASM PROTEINS; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS; UP-REGULATION;

EID: 77954676266     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-03-275651     Document Type: Article

References (47)

1. Baer R. TAL1, TAL2 and LYL1: a family of basic helix-loop-helix proteins implicated in T cell acute leukaemia. Semin Cancer Biol. 1993;4(6):341-347.
2. Robb L, Lyons I, Li R, et al. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. Proc Natl Acad Sci U S A. 1995;92(15):7075-7079.
3. Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. Nature. 1995;373(6513):432- 434.
4. Porcher C, Swat W, Rockwell K, Fujiwara Y, Alt FW, Orkin SH. The T cell leukemia oncoprotein SCL/tal-1 is essential for development of all hematopoietic lineages. Cell. 1996;86(1):47-57. (Pubitemid 26256577)
5. Robb L, Elwood NJ, Elefanty AG, et al. The scl gene product is required for the generation of all hematopoietic lineages in the adult mouse. EMBO J. 1996;15(16):4123-4129. (Pubitemid 26278695)
6. Visvader JE, Fujiwara Y, Orkin SH. Unsuspected role for the T-cell leukemia protein SCL/tal-1 in vascular development. Genes Dev. 1998;12(4):473-479. (Pubitemid 28101010)
7. Gering M, Rodaway AR, Gottgens B, Patient RK, Green AR. The SCL gene specifies haemangioblast development from early mesoderm. EMBO J. 1998;17(14):4029-4045. (Pubitemid 28333987)
8. Porcher C, Liao EC, Fujiwara Y, Zon LI, Orkin SH. Specification of hematopoietic and vascular development by the bHLH transcription factor SCL without direct DNA binding. Development. 1999;126(20):4603-4615.
9. Gering M, Yamada Y, Rabbitts TH, Patient RK. Lmo2 and Scl/Tal1 convert non-axial mesoderm into haemangioblasts which differentiate into endothelial cells in the absence of Gata1. Development. 2003;130(25):6187-6199. (Pubitemid 38008818)
10. Patterson LJ, Gering M, Patient R. Scl is required for dorsal aorta as well as blood formation in zebrafish embryos. Blood. 2005;105(9):3502-3511. (Pubitemid 40628192)
11. Capron C, Lecluse Y, Kaushik AL, et al. The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. Blood. 2006;107(12):4678-4686. (Pubitemid 43882615)
12. Schlaeger TM, Schuh A, Flitter S, et al. Decoding hematopoietic specificity in the helix-loop-helix domain of the transcription factor SCL/Tal-1. Mol Cell Biol. 2004;24(17):7491-7502. (Pubitemid 39121477)
13. Souroullas GP, Salmon JM, Sablitzky F, Curtis DJ, Goodell MA. Adult hematopoietic stem and progenitor cells require either Lyl1 or Scl for survival. Cell Stem Cell. 2009;4(2):180-186.
14. Chan WY, Follows GA, Lacaud G, et al. The paralogous hematopoietic regulators Lyl1 and Scl are coregulated by Ets and GATA factors, but Lyl1 cannot rescue the early Scl-/- phenotype. Blood. 2007;109(5):1908-1916. (Pubitemid 46348186)
15. Ferrier R, Nougarede R, Doucet S, Kahn-Perles B, Imbert J, Mathieu-Mahul D. Physical interaction of the bHLH LYL1 protein and NF-kappaB1 p105. Oncogene. 1999;18(4):995-1005. (Pubitemid 29086276)
16. San-Marina S, Han Y, Suarez Saiz F, Trus MR, Minden MD. Lyl1 interacts with CREB1 and alters expression of CREB1 target genes. Biochim Biophys Acta. 2008;1783(3):503-517.
17. Giroux S, Kaushik AL, Capron C, et al. lyl-1 and tal-1/scl, two genes encoding closely related bHLH transcription factors, display highly overlapping expression patterns during cardiovascular and hematopoietic ontogeny. Gene Expr Patterns. 2007;7(3):215-226. (Pubitemid 44841785)
18. Kallianpur AR, Jordan JE, Brandt SJ. The SCL/TAL-1 gene is expressed in progenitors of both the hematopoietic and vascular systems during embryogenesis. Blood. 1994;83(5):1200-1208.
19. Pulford K, Lecointe N, Leroy VK, Jones M, Mathieu MD, Mason DY. Expression of TAL-1 proteins in human tissues. Blood. 1995;85(3):675-684.
20. Chetty R, Dada MA, Boshoff CH, et al. TAL-1 protein expression in vascular lesions. J Pathol. 1997;181(3):311-315. (Pubitemid 27156845)
21. Tang T, Shi Y, Opalenik SR, et al. Expression of the TAL1/SCL transcription factor in physiological and pathological vascular processes. J Pathol. 2006;210(1):121-129. (Pubitemid 44288188)
22. Lazrak M, Deleuze V, Noel D, et al. The bHLH TAL-1/SCL regulates endothelial cell migration and morphogenesis. J Cell Sci. 2004;117(Pt 7):1161-1171. (Pubitemid 38456097)
23. Deleuze V, Chalhoub E, El-Hajj R, et al. TAL-1/SCL and its partners E47 and LMO2 up-regulate VE-cadherin expression in endothelial cells. Mol Cell Biol. 2007;27(7):2687-2697. (Pubitemid 46581358)
24. Yang J, Chang E, Cherry AM, et al. Human endothelial cell life extension by telomerase expression. J Biol Chem. 1999;274(37):26141-26148. (Pubitemid 129520040)
25. Leroy-Viard K, Vinit MA, Lecointe N, et al. Loss of TAL-1 protein activity induces premature apoptosis of Jurkat leukemic T cells upon medium depletion. EMBO J. 1995;14(10):2341-2349.
26. Masson VV, Devy L, Grignet-Debrus C, et al. Mouse Aortic Ring Assay: A New Approach of the Molecular Genetics of Angiogenesis. Biol Proced Online. 2002;4:24-31. (Pubitemid 35455116)
27. Davis GE, Bayless KJ, Mavila A. Molecular basis of endothelial cell morphogenesis in three-dimensional extracellular matrices. Anat Rec. 2002;268(3):252-275. (Pubitemid 35246845)
28. von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Exp Cell Res. 2006;312(5):623-629.
29. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol. 2002;160(3):985-1000. (Pubitemid 34224587)
30. Nasarre P, Thomas M, Kruse K, et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 2009;69(4):1324-1333.
31. Lin MI, Yu J, Murata T, Sessa WC. Caveolin-1-deficient mice have increased tumor microvascular permeability, angiogenesis, and growth. Cancer Res. 2007;67(6):2849-2856. (Pubitemid 46548975)
32. Visvader J, Begley CG, Adams JM. Differential expression of the LYL, SCL and E2A helix-loop-helix genes within the hemopoietic system. Oncogene. 1991;6(2):187-194. (Pubitemid 21902662)
33. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer. 2008;8(8):618-631.
34. Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell. 2009;16(2):209-221.
35. Fukuhara S, Sakurai A, Sano H, et al. Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway. Mol Cell Biol. 2005;25(1):136-146. (Pubitemid 40039806)
36. Kooistra MR, Dube N, Bos JL. Rap1: a key regulator in cell-cell junction formation. J Cell Sci. 2007;120(pt 1):17-22. (Pubitemid 46206645)
37. Pannekoek WJ, Kooistra MR, Zwartkruis FJ, Bos JL. Cell-cell junction formation: The role of Rap1 and Rap1 guanine nucleotide exchange factors. Biochim Biophys Acta. 2009;1788(4):790-796.
38. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer. 2008;8(8):604-617.
39. Gratton JP, Lin MI, Yu J, et al. Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice. Cancer Cell. 2003;4(1):31-39. (Pubitemid 36904159)
40. Satchi-Fainaro R, Mamluk R, Wang L, et al. Inhibition of vessel permeability by TNP-470 and its polymer conjugate, caplostatin. Cancer Cell. 2005;7(3):251-261. (Pubitemid 40568684)
41. Strilić B, Kucera T, Eglinger J, et al. The molecular basis of vascular lumen formation in the developing mouse aorta. Dev Cell. 2009;17(4):505-515.
42. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009;10(3):165-177.
43. Fiedler U, Scharpfenecker M, Koidl S, et al. The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies. Blood. 2004;103(11):4150-4156. (Pubitemid 38685356)
44. Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008;456(7223):809-813.
45. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62.
46. Jacobson JR, Garcia JG. Novel therapies for microvascular permeability in sepsis. Curr Drug Targets. 2007;8(4):509-514.
47. Rigau V, Morin M, Rousset MC, et al. Angiogenesis is associated with blood-brain barrier permeability in temporal lobe epilepsy. Brain. 2007;130(pt 7):1942-1956. (Pubitemid 47343810)